CLINICAL TRIAL: BETA-AMYLOID PROBES OF ALZHEIMER'S DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们的目的是检验3个假设：1)PET成像显示AD患者受AD影响的脑区FDDNP浓度最高，MCI为中等浓度，而年龄匹配的对照组最低。2)FDDNP-PET和FDG-PET成像模式呈负相关。3)携带APOE-4基因的受试者脑内FDDNP浓度高于无此遗传风险的受试者。这些研究最终可能为1)早期症状前诊断和2)监测疾病进展和新的药物干预的有效性提供一种安全、有效和实用的手段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our aim is to test 3 hypotheses: 1)PET imaging shows highest FDDNP concentrations in AD-affected brain regions in AD patients, intermediate concentrations in MCI, and lowest in age-matched controls. 2)FDDNP-PET and FDG-PET imaging patterns are inversely correlated. 3)Subjects with APOE-4 have greater FDDNP brain concentrations than those without this genetic risk for AD. These studies may eventually provide a safe, effective, and practical means for 1) early presymtomatic diagnosis, and 2) monitoring disease progression and efficacy of novel pharmacologic interventions.